<DOC>
	<DOCNO>NCT00021645</DOCNO>
	<brief_summary>This study evaluate whether vitamin E help treat swell macular area retina ( back part eye ) associate uveitis ( inflammatory eye disease ) . The macula responsible sharp vision ; swell area one cause vision loss uveitis patient . Macular swell also associate eye problem related diabetes . In patient , swell thought cause substance call vascular endothelial growth factor , VEGF . High dose vitamin E use treat eye problem diabetic . This study first step find vitamin E help reduce retinal swell uveitis , may also cause VEGF . Patients 9 year age old macular edema associate uveitis may eligible study . Candidates screen follow test procedure : - Medical history physical examination . This include measurement vital sign ( blood pressure , pulse , temperature breathe rate ) examination head neck , heart , lung , abdomen , arm legs . - Eye examination . This include measurement visual acuity use vision chart , measurement eye pressure examination pupils eye movement . The pupil dilate drop permit examination back eye . - Fluorescein angiography . This test use yellow dye ( fluorescein ) take photos retina . The fluorescein inject arm vein travel blood vessel eye . The camera flash blue light eye take picture retina . The picture show dye leak blood vessel retina . - Stereoscopic color fundus photography . These photograph back eye , take pupil dilate drop . - Optical coherence tomography . This test measure macular swell . It use determine swell get bad , good stay . - Blood test . About tablespoon blood drawn measure inflammation cell count side effect treatment . - Pregnancy test . All woman child-bearing potential tested pregnancy . Participants randomly assign daily treatment oral high-dose vitamin E ( 1600 unit ) placebo ( pill active ingredient ) 4 month . They examine 2 month 4 month test perform screen return final clinic visit 1 month treatment end .</brief_summary>
	<brief_title>Vitamin E Treat Uveitis-Associated Macular Edema</brief_title>
	<detailed_description>We plan test efficacy alpha-tocopherol ( vitamin E ) , potent inhibitor protein kinase C pathway vascular endothelial growth factor ( VEGF ) induce vascular permeability , treatment uveitis-associated macular edema . This perform use double-masked , randomize study uveitis patient macular edema receive either alpha-tocopherol placebo . This study consider pilot study provide information design outcome measurement development large , definitive , future study . Patients receive 1600IU/day Vitamin E placebo 4 month . The primary outcome visual acuity increase 10 letter baseline month 4 . Secondary outcome total area leakage macular height determine fluorescein angiography , change CME measure stereoscopic color photograph , optical coherence tomography ( OCT ) , need periocular injection additional systemic immunomodulatory medication , NEI VFQ summary score .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients document cystoid macular edema associate intraocular inflammatory disease . This documented clinical examination fluorescein angiography agree upon two independent observer . Patients must least one eye best correct visual acuity 20/32 le ( measure ETDRS chart ) macular edema . These consider eligible eye . A patient must lease one eligible eye clinical opacity grade less equal 1+ posterior subcapsular opacity less equal 2+ nuclear opacity . Patients 9 year , either sex ( nonpregnant female ) , carry diagnosis endogenous anterior , intermediate , posterior , panuveitis . Patients may receive systemic therapy treatment cystoid macular edema , may treat cystoid macular edema past . Vitreous haze eye equal less 1+ cell 1+ haze . The patient patient 's guardian must understand sign protocol inform consent and/or assent document . EXCLUSION CRITERIA : Periocular injection steroid within previous month potential need injection study . Systemic immunomodulatory agent ( ) add increase dosage ( great 20 % ) within last two month , potential need increase study . Patients require prednisone great 30 mg per day time enrollment . Vitamin E supplementation amount multivitamin ( 60 IU/day ) one month prior entry study . History hypersensitivity fluorescein . Unclear medium precludes assessment cystoid macular edema eligible eye ( ) , cataract vitreal opacity . Evidence macular subretinal neovascular net macular hole eligible eye ( ) . Prior current macular detachment eligible eye ( ) . Concurrent coumadin ( warfarin ) therapy know bleeding diathesis . Concurrent treatment new investigational drug . Malabsorption syndrome . Concurrent administration anticholesterol resin medication ( e.g . cholestyramine ) . Concurrent administration antiobesity drug orlistat . Pregnant lactating woman . Medical problem make consistent followup treatment period unlikely ( e.g . stroke , severe myocardial infarction , terminal carcinoma ) . Inability comply study requirement . Severe optic nerve atrophy eligible eye ( ) . History intercranial bleeds .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2004</verification_date>
	<keyword>Corticosteroids</keyword>
	<keyword>Immunosuppressives</keyword>
	<keyword>Intraocular Inflammatory Disease</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Macular Edema</keyword>
</DOC>